AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23481666 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma concentrations of lipopolysaccharide, soluble CD14, and intestinal fatty acid‐binding protein
Number of subjects: 0
Study 23481666 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemokine and cytokine responses of peripheral blood mononuclear cells stimulated with TLR2, 4, or 7/8 agonists
Number of subjects: 0
Study 20938770 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete supine position
Number of subjects: 33
Study 20938770 — intervention group
Group type: COMPARATOR
Intervention: Prone position
Number of subjects: 33
Study 19781316 — intervention group
Group type: EXPERIMENTAL
Intervention: upstream tirofiban
Number of subjects: 160
Study 19781316 — intervention group
Group type: COMPARATOR
Intervention: downstream tirofiban
Number of subjects: 160
Study 17206703 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg/kg infliximab (IFX)
Number of subjects: 100
Study 17206703 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-dose IFX induction at weeks 0, 2, and 6
Number of subjects: 100
Study 17206703 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab (IFX)
Number of subjects: 100
Study 17206703 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab (IFX) for acute steroid-refractory colitis
Number of subjects: 100
Study 17206703 — intervention group
Group type: EXPERIMENTAL
Intervention: Age of patients
Number of subjects: 100
Study 14739846 — intervention group
Group type: EXPERIMENTAL
Intervention: DPRHP
Number of subjects: 57
Study 14739846 — intervention group
Group type: EXPERIMENTAL
Intervention: P-JS
Number of subjects: 57
Study 14739846 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 57
Study 11238498 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal estradiol (80-microg patches) + oral norethisterone (1 mg daily)
Number of subjects: 43
Study 11238498 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study 9755259 — intervention group
Group type: EXPERIMENTAL
Intervention: xylitol syrup
Number of subjects: 857
Study 9755259 — intervention group
Group type: EXPERIMENTAL
Intervention: xylitol chewing gum
Number of subjects: 857
Study 9755259 — intervention group
Group type: EXPERIMENTAL
Intervention: xylitol lozenge
Number of subjects: 857
Study 9755259 — intervention group
Group type: COMPARATOR
Intervention: control syrup
Number of subjects: 857
Study 9755259 — intervention group
Group type: COMPARATOR
Intervention: control chewing gum
Number of subjects: 857
Study 9755259 — intervention group
Group type: COMPARATOR
Intervention: control lozenge
Number of subjects: 857
Study 7851110 — intervention group
Group type: EXPERIMENTAL
Intervention: Mantel‐Haenszel (MH) method
Number of subjects: 0
Study 7851110 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximum likelihood (MLE) method
Number of subjects: 0
Study 7851110 — intervention group
Group type: EXPERIMENTAL
Intervention: Observed to expected ratio (O/E) method
Number of subjects: 0
Study 7851110 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 3245292 — intervention group
Group type: EXPERIMENTAL
Intervention: Concentrated human diploid cell vaccine (HDCV) with human rabies immune globulin (HRIG)
Number of subjects: 0
Study 3245292 — intervention group
Group type: EXPERIMENTAL
Intervention: Concentrated and purified human diploid cell vaccine (HDCV) with human rabies immune globulin (HRIG)
Number of subjects: 0
Study 29466682 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute hypoxia (fraction of inspired oxygen = 0.12)
Number of subjects: 10
Study 29466682 — intervention group
Group type: COMPARATOR
Intervention: Normoxia (ambient air)
Number of subjects: 10
Study 27007272 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal ropivacaine irrigation
Number of subjects: 110
Study 27007272 — intervention group
Group type: COMPARATOR
Intervention: Intraperitoneal normal saline irrigation
Number of subjects: 110
Study 25151541 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural oil-based emulsion containing allantoin (cream 1)
Number of subjects: 174
Study 25151541 — intervention group
Group type: COMPARATOR
Intervention: Aqueous cream (cream 2)
Number of subjects: 174
Study 22507631 — intervention group
Group type: EXPERIMENTAL
Intervention: 3mg melatonin
Number of subjects: 36
Study 22507631 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 20033409 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose methylprednisolone (10 mg/kg/die for 3 days, then 2.5 mg/kg/die)
Number of subjects: 60
Study 20033409 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose methylprednisolone (1 mg/kg/die for 3 days, then 2.5 mg/kg/die)
Number of subjects: 60
Study 20033409 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose methylprednisolone
Number of subjects: 60
Study 18165082 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical diclofenac 0.1%
Number of subjects: 142
Study 18165082 — intervention group
Group type: COMPARATOR
Intervention: Topical betamethasone 0.1%
Number of subjects: 142
Study 15679716 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled budesonide (BUD) 800 mug daily for 3 months
Number of subjects: 0
Study 15679716 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 12903699 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternity support binder worn while awake for 2 weeks
Number of subjects: 40
Study 12903699 — intervention group
Group type: COMPARATOR
Intervention: Comparison group (no binder for 2 weeks)
Number of subjects: 40
Study 10336792 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam 0.75 mg
Number of subjects: 19
Study 10336792 — intervention group
Group type: COMPARATOR
Intervention: Alprazolam (0, 0.25, 0.50, 0.75 mg)
Number of subjects: 19
Study 9136458 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated fractionation
Number of subjects: 105
Study 9136458 — intervention group
Group type: COMPARATOR
Intervention: Conventional fractionation
Number of subjects: 105
Study 1951401 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulizer Chronolog (electronic recording device)
Number of subjects: 0
Study 1951401 — intervention group
Group type: COMPARATOR
Intervention: Self-reporting
Number of subjects: 0
Study 1951401 — intervention group
Group type: COMPARATOR
Intervention: Canister weighing
Number of subjects: 0
Study 1951401 — intervention group
Group type: EXPERIMENTAL
Intervention: Informed participants using the Nebulizer Chronolog
Number of subjects: 0
Study 6894819 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin
Number of subjects: 175
Study 6894819 — intervention group
Group type: EXPERIMENTAL
Intervention: Azidocillin
Number of subjects: 175
Study 6894819 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylpropanolamine
Number of subjects: 175
Study 6894819 — intervention group
Group type: EXPERIMENTAL
Intervention: Pivampicillin
Number of subjects: 175
Study 31187282 — intervention group
Group type: EXPERIMENTAL
Intervention: High‐intensity interval training (HIIT)
Number of subjects: 20
Study 31187282 — intervention group
Group type: COMPARATOR
Intervention: Moderate‐intensity training (CONT)
Number of subjects: 20
Study 27578365 — intervention group
Group type: EXPERIMENTAL
Intervention: Esketamine (Ketanest S®) administered intravenously during a 55 min resting-state fMRI scan
Number of subjects: 35
Study 27578365 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 27639637 — intervention group
Group type: EXPERIMENTAL
Intervention: Gauze impregnated in epinephrine
Number of subjects: 99
Study 27639637 — intervention group
Group type: COMPARATOR
Intervention: Aluminum chloride
Number of subjects: 99
Study 24943252 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive Iterative Dose Reduction (AIDR) 3D
Number of subjects: 200
Study 24943252 — intervention group
Group type: COMPARATOR
Intervention: Filtered Back Projection (FBP)
Number of subjects: 200
Study 24943252 — intervention group
Group type: EXPERIMENTAL
Intervention: Wide-detector technique with AIDR 3D
Number of subjects: 200
Study 24943252 — intervention group
Group type: COMPARATOR
Intervention: Helical technique with AIDR 3D
Number of subjects: 200
Study 22987083 — intervention group
Group type: EXPERIMENTAL
Intervention: Patupilone (10 mg/m² intravenously every 3 weeks)
Number of subjects: 829
Study 22987083 — intervention group
Group type: COMPARATOR
Intervention: Pegylated liposomal doxorubicin (PLD) (50 mg/m² intravenously every 4 weeks)
Number of subjects: 829
Study 22987083 — intervention group
Group type: EXPERIMENTAL
Intervention: Patupilone
Number of subjects: 829
Study 22987083 — intervention group
Group type: COMPARATOR
Intervention: PLD
Number of subjects: 829
Study 21246846 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominal acupuncture plus Long's bone-setting manipulation (combined therapy)
Number of subjects: 180
Study 21246846 — intervention group
Group type: COMPARATOR
Intervention: Long's bone-setting manipulation (bone-setting group)
Number of subjects: 180
Study 21246846 — intervention group
Group type: COMPARATOR
Intervention: Abdominal acupuncture (abdominal acupuncture group)
Number of subjects: 180
Study 18378456 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai Chi
Number of subjects: 33
Study 18378456 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 33
Study 15719319 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral superior oblique palsy
Number of subjects: 20
Study 15719319 — intervention group
Group type: COMPARATOR
Intervention: Unilateral superior oblique palsy
Number of subjects: 20
Study 12887127 — intervention group
Group type: EXPERIMENTAL
Intervention: HRT (0.625 mg of conjugated equine estrogen combined with 2.5 mg of medroxyprogesterone acetate) for 12 months in HT-HRT group
Number of subjects: 97
Study 12887127 — intervention group
Group type: EXPERIMENTAL
Intervention: HRT (0.625 mg of conjugated equine estrogen combined with 2.5 mg of medroxyprogesterone acetate) for 12 months in NT-HRT group
Number of subjects: 97
Study 12887127 — intervention group
Group type: COMPARATOR
Intervention: Control group (no HRT) in HT-Control group
Number of subjects: 97
Study 12887127 — intervention group
Group type: COMPARATOR
Intervention: Control group (no HRT) in NT-Control group
Number of subjects: 97
Study 10365610 — intervention group
Group type: EXPERIMENTAL
Intervention: Mivacurium (0.25 mg/kg; 3 x SD95)
Number of subjects: 82
Study 10365610 — intervention group
Group type: COMPARATOR
Intervention: Succinylcholine (1 mg/kg)
Number of subjects: 82
Study 8724880 — intervention group
Group type: EXPERIMENTAL
Intervention: Total gastrectomy or Billroth II gastric resection
Number of subjects: 21
Study 8724880 — intervention group
Group type: COMPARATOR
Intervention: Cholecystectomy
Number of subjects: 21
Study 8724880 — intervention group
Group type: EXPERIMENTAL
Intervention: Total gastrectomy
Number of subjects: 21
Study 8724880 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastric resection
Number of subjects: 21
Study 8370422 — intervention group
Group type: EXPERIMENTAL
Intervention: NOP regimen (mitoxantrone 16 mg/m2, vincristine 2 mg, prednisolone 250 mg day 1-4 and 17-20)
Number of subjects: 151
Study 8370422 — intervention group
Group type: COMPARATOR
Intervention: M+P regimen (melphalan 0.25 mg/kg and prednisolone 100-200 mg/day day 1-4)
Number of subjects: 151
Study 8370422 — intervention group
Group type: EXPERIMENTAL
Intervention: NOP regimen
Number of subjects: 151
Study 8370422 — intervention group
Group type: COMPARATOR
Intervention: M+P regimen
Number of subjects: 151
Study 3530633 — intervention group
Group type: EXPERIMENTAL
Intervention: Copper T 220 C
Number of subjects: 200
Study 3530633 — intervention group
Group type: COMPARATOR
Intervention: Alza T IPCS 52
Number of subjects: 200
Study 31823654 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy (NAC) with nivolumab
Number of subjects: 0
Study 31823654 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy (NAC) with nivolumab and linrodostat mesylate
Number of subjects: 0
Study 31823654 — intervention group
Group type: EXPERIMENTAL
Intervention: Postsurgery nivolumab
Number of subjects: 0
Study 31823654 — intervention group
Group type: EXPERIMENTAL
Intervention: Postsurgery nivolumab with linrodostat
Number of subjects: 0
Study 30189846 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-based primary care intervention (Guided Care model)
Number of subjects: 1218
Study 30189846 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 1218
Study 27450438 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute high-intensity exercise (n = 29)
Number of subjects: 58
Study 27450438 — intervention group
Group type: COMPARATOR
Intervention: Non-exercise control (n = 29)
Number of subjects: 58
Study 24449733 — intervention group
Group type: EXPERIMENTAL
Intervention: Simpson biplane method with good image quality
Number of subjects: 63
Study 24449733 — intervention group
Group type: EXPERIMENTAL
Intervention: Teichholz method with poor image quality
Number of subjects: 63
Study 24449733 — intervention group
Group type: EXPERIMENTAL
Intervention: Teichholz method with good image quality
Number of subjects: 63
Study 24449733 — intervention group
Group type: EXPERIMENTAL
Intervention: Eyeball method
Number of subjects: 63
Study 24188894 — intervention group
Group type: EXPERIMENTAL
Intervention: Anacetrapib
Number of subjects: 1398
Study 24188894 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1398
Study 21800179 — intervention group
Group type: EXPERIMENTAL
Intervention: Consistent condom use with commercial sex partners
Number of subjects: 418
Study 21800179 — intervention group
Group type: EXPERIMENTAL
Intervention: Consistent condom use with girlfriends
Number of subjects: 418
Study 21800179 — intervention group
Group type: EXPERIMENTAL
Intervention: Consistent condom use with other non-commercial partners
Number of subjects: 418
Study 21800179 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV prevalence
Number of subjects: 418
Study 21800179 — intervention group
Group type: EXPERIMENTAL
Intervention: Syphilis prevalence
Number of subjects: 418
Study 21800179 — intervention group
Group type: EXPERIMENTAL
Intervention: HSV-2 prevalence
Number of subjects: 418
Study 21800179 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall prevalence for any STI
Number of subjects: 418
Study 21800179 — intervention group
Group type: EXPERIMENTAL
Intervention: Factors associated with HIV/STIs
Number of subjects: 418
Study 19895770 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased therapist structure during aftercare treatment
Number of subjects: 247
Study 17255277 — intervention group
Group type: EXPERIMENTAL
Intervention: Epirubicin
Number of subjects: 177
Study 17255277 — intervention group
Group type: COMPARATOR
Intervention: Epirubicin + Tamoxifen
Number of subjects: 177
Study 17255277 — intervention group
Group type: EXPERIMENTAL
Intervention: HAI-2 expression
Number of subjects: 177
Study 15767638 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose cyclophosphamide, cisplatin, and carmustine (HD-CPB) with stem-cell support
Number of subjects: 785
Study 15767638 — intervention group
Group type: COMPARATOR
Intervention: Intermediate-dose cyclophosphamide, cisplatin, and carmustine (ID-CPB) with G-CSF support
Number of subjects: 785
Study 12472325 — intervention group
Group type: EXPERIMENTAL
Intervention: IMPACT intervention (n = 906)
Number of subjects: 1801
Study 12472325 — intervention group
Group type: COMPARATOR
Intervention: Usual care (n = 895)
Number of subjects: 1801
Study 9559801 — intervention group
Group type: EXPERIMENTAL
Intervention: 750 mg levofloxacin
Number of subjects: 16
Study 9559801 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g levofloxacin
Number of subjects: 16
Study 9559801 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 8963007 — intervention group
Group type: EXPERIMENTAL
Intervention: Dimethyl ether-propane cryogenic spray (DMEP)
Number of subjects: 124
Study 8963007 — intervention group
Group type: COMPARATOR
Intervention: Liquid nitrogen (LN)
Number of subjects: 124
Study 1858160 — intervention group
Group type: EXPERIMENTAL
Intervention: OKT3 for the first 14 days after OLT with low-dose steroids
Number of subjects: 46
Study 1858160 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporine, steroids, and azathioprine
Number of subjects: 46
Study 1858160 — intervention group
Group type: EXPERIMENTAL
Intervention: OKT3
Number of subjects: 46
Study 1858160 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporine
Number of subjects: 46
Study 6133803 — intervention group
Group type: EXPERIMENTAL
Intervention: Timiperone (1.0 mg/tablet, daily dose of 1-3 tablets for the first day, up to 12 tablets for 12 weeks)
Number of subjects: 206
Study 6133803 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol (1.5 mg/tablet, daily dose of 1-3 tablets for the first day, up to 12 tablets for 12 weeks)
Number of subjects: 206
Study 6133803 — intervention group
Group type: EXPERIMENTAL
Intervention: Timiperone
Number of subjects: 206
Study 30837255 — intervention group
Group type: EXPERIMENTAL
Intervention: Coaching intervention for the first 6 months
Number of subjects: 30
Study 30837255 — intervention group
Group type: COMPARATOR
Intervention: Standard care and printed information about healthy lifestyles
Number of subjects: 30
Study 30101824 — intervention group
Group type: EXPERIMENTAL
Intervention: Ephedrine 10 mg
Number of subjects: 40
Study 30101824 — intervention group
Group type: EXPERIMENTAL
Intervention: Etilefrine 2 mg
Number of subjects: 40
Study 26806318 — intervention group
Group type: EXPERIMENTAL
Intervention: Video discharge instructions in addition to standard discharge instructions
Number of subjects: 63
Study 26806318 — intervention group
Group type: COMPARATOR
Intervention: Standard discharge instructions (Control)
Number of subjects: 63
Study 26806318 — intervention group
Group type: EXPERIMENTAL
Intervention: Video discharge instructions for caregivers with less than a high school education
Number of subjects: 63
Study 26806318 — intervention group
Group type: COMPARATOR
Intervention: Standard discharge instructions for caregivers with less than a high school education (Control)
Number of subjects: 63
Study 26806318 — intervention group
Group type: EXPERIMENTAL
Intervention: Video discharge instructions for caregivers with more than a high school education
Number of subjects: 63
Study 26806318 — intervention group
Group type: COMPARATOR
Intervention: Standard discharge instructions for caregivers with more than a high school education (Control)
Number of subjects: 63
Study 25245954 — intervention group
Group type: EXPERIMENTAL
Intervention: LIFE intervention (28 group sessions over 12 months)
Number of subjects: 210
Study 25245954 — intervention group
Group type: COMPARATOR
Intervention: Standard of care control group (two dietitian-led diabetes self-management classes)
Number of subjects: 210
Study 22527894 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyaluronan-enriched transfer medium (HETM) (0.5 mg/ml hyaluronan)
Number of subjects: 314
Study 22527894 — intervention group
Group type: COMPARATOR
Intervention: Control medium (no hyaluronan)
Number of subjects: 314
Study 22527894 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyaluronan-enriched transfer medium (HETM)
Number of subjects: 314
Study 19172627 — intervention group
Group type: EXPERIMENTAL
Intervention: Dex‐P (4 mg/ml) continuously applied for 14 days via a round window catheter
Number of subjects: 23
Study 19172627 — intervention group
Group type: COMPARATOR
Intervention: Placebo (NaCl 0.9%) continuously applied for 14 days via a round window catheter
Number of subjects: 23
Study 19172627 — intervention group
Group type: EXPERIMENTAL
Intervention: Dex‐P (4 mg/ml) after 3 months follow-up
Number of subjects: 23
Study 19172627 — intervention group
Group type: EXPERIMENTAL
Intervention: Dex‐P (4 mg/ml)
Number of subjects: 23
Study 19172627 — intervention group
Group type: COMPARATOR
Intervention: Placebo (NaCl 0.9%)
Number of subjects: 23
Study 18096042 — intervention group
Group type: EXPERIMENTAL
Intervention: Hall Technique PMCs
Number of subjects: 132
Study 18096042 — intervention group
Group type: COMPARATOR
Intervention: Control restorations
Number of subjects: 132
Study 15188897 — intervention group
Group type: EXPERIMENTAL
Intervention: LASEK
Number of subjects: 42
Study 15188897 — intervention group
Group type: COMPARATOR
Intervention: PRK
Number of subjects: 42
Study 15188897 — intervention group
Group type: EXPERIMENTAL
Intervention: LASEK and PRK
Number of subjects: 42
Study 12420185 — intervention group
Group type: EXPERIMENTAL
Intervention: Tinnitus Retraining Therapy combined with cognitive behavioral group therapy
Number of subjects: 95
Study 12420185 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 95
Study 12420185 — intervention group
Group type: COMPARATOR
Intervention: Cognitive behavioral group therapy alone
Number of subjects: 95
Study 9716201 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilostazol
Number of subjects: 36
Study 9716201 — intervention group
Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 36
Study 7917733 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative multimodal analgesia regimen (morphine 0.15 mg kg‐1 i.m., perphenazine 0.03 mg kg‐1 i.m., indomethacin 100 mg rectal suppository)
Number of subjects: 30
Study 7917733 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative multimodal analgesia regimen
Number of subjects: 30
Study 7917733 — intervention group
Group type: COMPARATOR
Intervention: Placebo (midazolam 0.05 mg kg‐1 i.m. and placebo rectal suppository)
Number of subjects: 30
Study 7917733 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (treatment and placebo)
Number of subjects: 30
Study 2060256 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen 50 mg
Number of subjects: 298
Study 2060256 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen 100 mg
Number of subjects: 298
Study 2060256 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen 200 mg
Number of subjects: 298
Study 2060256 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen 100 mg + Caffeine 100 mg
Number of subjects: 298
Study 2060256 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen 200 mg + Caffeine 100 mg
Number of subjects: 298
Study 2060256 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 298
Study 6297368 — intervention group
Group type: EXPERIMENTAL
Intervention: Melphalan treatment for mucinous tumours in Stages Ia and Ib
Number of subjects: 142
Study 6297368 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy alone for other patients in Stage I and II
Number of subjects: 142
Study 6297368 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Melphalan and radiotherapy
Number of subjects: 142